Skip to search formSkip to main contentSkip to account menu

sarizotan

Known as: 1-(5-(4-fluorophenyl)pyridin-3-yl)-n-((2R)-3,4,4a,8a-tetrahydro-2h-chromen-2-ylmethyl)methanamine 
National Institutes of Health

Related topics

Related topics

3 relations

Narrower (2)

EMD128130sarizotan hydrochloride

Broader (1)

Organic Chemicals

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Extended-Release Amantadine-A Smart Pill for Treatment of Levodopa-Induced Dyskinesia but Does the Evidence Justify the Cost?
In this issue of JAMA Neurology, Pahwa and colleagues1 report the results of the ADS-5102 Extended Release Capsules for the… 
2012
2012
Intramolecular carbolithiation of N-allyl-ynamides: an efficient entry to 1,4-dihydropyridines and pyridines – application to a formal synthesis of sarizotan
We have developed a general synthesis of polysubstituted 1,4-dihydropyridines and pyridines based on a highly regioselective… 
2011
2011
Role of dopamine D3 and serotonin 5-HT1A receptors in l-DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson’s disease
Sarizotan, a 5-HT1A agonist with additional affinity for D3 and D4 receptors, has been demonstrated to have anti-dyskinetic… 
2010
2010
In Vitro Characterization of Sarizotan Metabolism: Hepatic Clearance, Identification and Characterization of Metabolites, Drug-Metabolizing Enzyme Identification, and Evaluation of Cytochrome P450…
In vitro biotransformation studies of sarizotan using human liver microsomes (HLM) showed aromatic and aliphatic… 
Highly Cited
2009
Highly Cited
2009
Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats
RationaleDyskinesia affects the majority of levodopa-treated parkinsonian patients within 5–10 years of treatment with levodopa… 
2007
2007
Investigation of the impact of sarizotan on the pharmacokinetics of levodopa
Objective. To investigate the effect of sarizotan on the pharmacokinetics of levodopa in fixed combination with carbidopa or… 
2007
2007
Pharmacokinetics of sarizotan after oral administration of single and repeat doses in healthy subjects.
OBJECTIVE Sarizotan is a 5-HTIA receptor agonist with high affinity for D3 and D4 receptors. Here we report the pharmacokinetic… 
2007
2007
Putative antipsychotics with pronounced agonism at serotonin 5-HT1A and partial agonist activity at dopamine D2 receptors disrupt basal PPI of the startle reflex in rats
IntroductionPrepulse inhibition (PPI) of the startle reflex has been extensively studied because it is disrupted in several… 
2006
2006
The novel antidyskinetic drug sarizotan elicits different functional responses at human D2-like dopamine receptors
2005
2005
Changes in sleep electroencephalogram and nocturnal hormone secretion after administration of the antidyskinetic agent sarizotan in healthy young male volunteers
RationaleSarizotan is a 5-HT1A agonist with high affinity to D3 and D4 receptors. In animal experiments, the drug shows a strong… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)